Ruilope Urioste, Luis Miguel Salazar, Jorge Segura de la Morena, Julián
Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. [artículo] - Expert opinion on investigational drugs, 2013 - 22(7):915-25.
Formato Vancouver:
Segura J, Salazar J, Ruilope LM. Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin Investig Drugs. 2013 Jul;22(7):915-25.
PMID: 23731190
Contiene 58 referencias
INTRODUCTION: Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed.
Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. [artículo] - Expert opinion on investigational drugs, 2013 - 22(7):915-25.
Formato Vancouver:
Segura J, Salazar J, Ruilope LM. Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin Investig Drugs. 2013 Jul;22(7):915-25.
PMID: 23731190
Contiene 58 referencias
INTRODUCTION: Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed.
